No Data
No Data
Day One Biopharm Is Maintained at Buy by Jones Trading
Day One Biopharmaceutical Analyst Ratings
Day One Biopharmaceuticals (DAWN) Posts Stellar Q3 but With Extreme Concentration Risk
JonesTrading Maintains Day One Biopharmaceuticals(DAWN.US) With Buy Rating, Cuts Target Price to $34
CBTN Partners With Day One to Drive New Therapies for Pediatric Brain Tumors
Piper Sandler Maintains Day One Biopharmaceuticals(DAWN.US) With Buy Rating, Maintains Target Price $40